Characteristics and Outcomes of Heart Transplant Recipients With Coronavirus-19 Disease in a High-volume Transplant Center

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMARCONDES-BRAGA, Fabiana G.
dc.contributor.authorMURAD, Ciro M.
dc.contributor.authorBELFORT, Deborah S. P.
dc.contributor.authorDANTAS, Rafael C. T.
dc.contributor.authorLIRA, Maria Tereza S. S.
dc.contributor.authorARAGAO, Carlos A. S.
dc.contributor.authorSICILIANO, Rinaldo F.
dc.contributor.authorMANGINI, Sandrigo
dc.contributor.authorSEGURO, Luis Fernando B. C.
dc.contributor.authorCAMPOS, Iascara W.
dc.contributor.authorAVILA, Monica S.
dc.contributor.authorBELLO, Mariana V. O.
dc.contributor.authorSANTOS, Fernanda B. A. dos
dc.contributor.authorV, Tania M. Strabelli
dc.contributor.authorGAIOTTO, Fabio A.
dc.contributor.authorBACAL, Fernando
dc.date.accessioned2022-04-19T13:09:33Z
dc.date.available2022-04-19T13:09:33Z
dc.date.issued2022
dc.description.abstractBackground. Heart transplant (HT) recipients may be at higher risk of acquiring SARS-CoV-2 infection and developing critical illness. The aim of this study is to describe characteristics and outcomes of HT recipients infected by SARS-COV-2, from a high-volume transplant center. Methods. We have described data of all adult HT recipients with confirmed coronavirus disease 2019 by RT-PCR in nasopharyngeal samples from April 5, 2020, to January 5, 2021. Outcomes and follow-up were recorded until February 5, 2021. Results. Forty patients were included. Twenty-four patients (60%) were men; the median age was 53 (40-60) y old; median HT time was 34 mo; and median follow-up time 162 d. The majority needed hospitalization (83%). Immunosuppressive therapy was reduced/withdrawn in the majority of patients, except from steroids, which were maintained. Seventeen patients (42.5%) were classified as having severe disease according to the ordinal scale developed by the World Health Organization Committee. They tended to have lower absolute lymphocyte count (P < 0.001) during follow-up when compared with patients with mild disease. Thirty-day mortality was 12.5%. However, a longer follow-up revealed increased later mortality (27.5%), with median time to death around 35 d. Bacterial nosocomial infections were a leading cause of death. Cardiac allograft rejection (10%) and ventricular dysfunction (12.5%) were also not negligible. Conclusions. Major findings of this study corroborate other cohorts' results, but it also reports significant rate of later events, suggesting that a strict midterm surveillance is advisable to HT recipients with coronavirus disease 2019.eng
dc.description.indexMEDLINEeng
dc.identifier.citationTRANSPLANTATION, v.106, n.3, p.641-647, 2022
dc.identifier.doi10.1097/TP.0000000000003770
dc.identifier.eissn1534-6080
dc.identifier.issn0041-1337
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/46227
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofTransplantation
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.subject.othersolid-organ transplanteng
dc.subject.othercovid-19eng
dc.subject.wosImmunologyeng
dc.subject.wosSurgeryeng
dc.subject.wosTransplantationeng
dc.titleCharacteristics and Outcomes of Heart Transplant Recipients With Coronavirus-19 Disease in a High-volume Transplant Centereng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalMURAD, Ciro M.:Univ Sao Paulo, Hosp Clin, Fac Med, Inst Coracao InCor, Sao Paulo, Brazil
hcfmusp.citation.scopus16
hcfmusp.contributor.author-fmusphcFABIANA GOULART MARCONDES BRAGA
hcfmusp.contributor.author-fmusphcDEBORAH DE SA PEREIRA BELFORT
hcfmusp.contributor.author-fmusphcRAFAEL CAVALCANTI TOURINHO DANTAS
hcfmusp.contributor.author-fmusphcMARIA TEREZA SAMPAIO DE SOUSA LIRA
hcfmusp.contributor.author-fmusphcCARLOS AURELIO SANTOS ARAGAO
hcfmusp.contributor.author-fmusphcRINALDO FOCACCIA SICILIANO
hcfmusp.contributor.author-fmusphcSANDRIGO MANGINI
hcfmusp.contributor.author-fmusphcLUIS FERNANDO BERNAL DA COSTA SEGURO
hcfmusp.contributor.author-fmusphcIASCARA WOZNIAK DE CAMPOS
hcfmusp.contributor.author-fmusphcMONICA SAMUEL AVILA GRINBERG
hcfmusp.contributor.author-fmusphcMARIANA VIEIRA DE OLIVEIRA BELLO
hcfmusp.contributor.author-fmusphcFERNANDA BARONE ALVES DOS SANTOS
hcfmusp.contributor.author-fmusphcTANIA MARA VAREJAO STRABELLI
hcfmusp.contributor.author-fmusphcFABIO ANTONIO GAIOTTO
hcfmusp.contributor.author-fmusphcFERNANDO BACAL
hcfmusp.description.beginpage641
hcfmusp.description.endpage647
hcfmusp.description.issue3
hcfmusp.description.volume106
hcfmusp.origemWOS
hcfmusp.origem.pubmed33756548
hcfmusp.origem.scopus2-s2.0-85105436865
hcfmusp.origem.wosWOS:000759088200045
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAkalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117eng
hcfmusp.relation.referenceAlberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001eng
hcfmusp.relation.referenceAli T, 2021, TRANSPLANTATION, V105, P121, DOI 10.1097/TP.0000000000003433eng
hcfmusp.relation.referenceAvery RK, 2021, TRANSPLANTATION, V105, P56, DOI 10.1097/TP.0000000000003519eng
hcfmusp.relation.referenceAzzi Y, 2021, TRANSPLANTATION, V105, P37, DOI 10.1097/TP.0000000000003523eng
hcfmusp.relation.referenceBottio T, 2021, JACC-HEART FAIL, V9, P52, DOI 10.1016/j.jchf.2020.10.009eng
hcfmusp.relation.referenceBuetti N, 2021, INTENS CARE MED, V47, P180, DOI 10.1007/s00134-021-06346-weng
hcfmusp.relation.referenceCaillard S, 2020, KIDNEY INT, V98, P1549, DOI 10.1016/j.kint.2020.08.005eng
hcfmusp.relation.referenceChapman JR, 2021, TRANSPLANTATION, V105, P1, DOI 10.1097/TP.0000000000003544eng
hcfmusp.relation.referenceClancy CJ, 2020, JAC-ANTIMICROB RESIS, V2, DOI 10.1093/jacamr/dlaa049eng
hcfmusp.relation.referenceColl E, 2021, AM J TRANSPLANT, V21, P1825, DOI 10.1111/ajt.16369eng
hcfmusp.relation.referenceCorman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045eng
hcfmusp.relation.referenceCravedi P, 2020, AM J TRANSPLANT, V20, P3140, DOI 10.1111/ajt.16185eng
hcfmusp.relation.referenceCrespo M, 2020, AM J TRANSPLANT, V20, P2883, DOI 10.1111/ajt.16096eng
hcfmusp.relation.referenceFelldin M, 2021, TRANSPLANTATION, V105, P108, DOI 10.1097/TP.0000000000003436eng
hcfmusp.relation.referenceFernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929eng
hcfmusp.relation.referenceHorby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]eng
hcfmusp.relation.referenceKates Olivia S, 2021, Clin Infect Dis, V73, pe4090, DOI 10.1093/cid/ciaa1097eng
hcfmusp.relation.referenceKutzler HL, 2021, TRANSPLANTATION, V105, pE6, DOI 10.1097/TP.0000000000003495eng
hcfmusp.relation.referenceLangford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016eng
hcfmusp.relation.referenceLatif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159eng
hcfmusp.relation.referenceLee K, 2009, GLOB INST, P1eng
hcfmusp.relation.referenceLi J, 2021, J MED VIROL, V93, P1449, DOI 10.1002/jmv.26424eng
hcfmusp.relation.referenceMinisterio da Saude, 2021, PAIN COReng
hcfmusp.relation.referencePereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941eng
hcfmusp.relation.referenceRivinius R, 2020, CLIN RES CARDIOL, V109, P1531, DOI 10.1007/s00392-020-01722-weng
hcfmusp.relation.referenceSiddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012eng
hcfmusp.relation.referenceTschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062eng
hcfmusp.relation.referenceWHO R&D Blueprint, 2020, NOV COR COVID 19 THEeng
hcfmusp.relation.referenceYi SG, 2020, TRANSPLANTATION, V104, P2208, DOI 10.1097/TP.0000000000003339eng
hcfmusp.relation.referenceZaidan M, 2021, TRANSPLANTATION, V105, P61, DOI 10.1097/TP.0000000000003536eng
hcfmusp.relation.referenceZhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3eng
hcfmusp.relation.referenceZhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication7c348265-ff8f-4bc2-8b2d-19a5019ec773
relation.isAuthorOfPublicationaa3a76a0-7ed4-42fa-8fd2-348016baca6b
relation.isAuthorOfPublicationd7d9429e-338a-4927-bd67-4996cca3dc58
relation.isAuthorOfPublicationb8a8124b-e83d-4115-a187-3bc35dcf47e9
relation.isAuthorOfPublicationb5b3d277-35b7-468f-b56a-cfad199f0af6
relation.isAuthorOfPublication669fd77c-1311-4f59-bbf3-b02cb3b39586
relation.isAuthorOfPublicationb97fd8ed-32e4-4450-bb28-f17092479c2b
relation.isAuthorOfPublicationc5b63c20-b4c6-47d6-909a-2370459c36a5
relation.isAuthorOfPublication266eedd1-e9ba-4887-9e21-87ed8d2d095a
relation.isAuthorOfPublicationabee5684-906e-45f9-bc53-ee09854cf0a3
relation.isAuthorOfPublicationc88b5489-689b-470f-ae36-00903124d670
relation.isAuthorOfPublication7c7763c0-a29c-4e35-ab0f-131f15e9c131
relation.isAuthorOfPublication7363aff2-b23d-4308-a6fe-995b7ad8697f
relation.isAuthorOfPublication7637f25f-9e46-4a41-bb9b-53e4ce6776a1
relation.isAuthorOfPublication2c246184-dfb8-4a5a-bc13-582dadb38d27
relation.isAuthorOfPublication.latestForDiscovery7c348265-ff8f-4bc2-8b2d-19a5019ec773
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MARCONDES-BRAGA_Characteristics_and_Outcomes_of_Heart_Transplant_Recipients_With_2022.PDF
Tamanho:
460.03 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - LIM/47
Artigos e Materiais de Revistas Científicas - ODS/03